Michael Vi/iStock Editorial by way of Getty Photos
- AbbVie (NYSE:ABBV) has accomplished its ~$8.7B ($45 per share) acquisition of Cerevel Therapeutics, giving it entry to a pipeline of neurological illness belongings.
- Cerevel’s newest stage asset, in part 3, is tavapadon for Parkinson’s illness. In part 2, the corporate has emraclidine for schizophrenia (additionally in part 1 Alzheimer’s illness psychosis), darigabat for epilepsy and panic dysfunction, and CVL-871 for dementia-related apathy
- AbbVie additionally reaffirmed its 2024 full-year adjusted diluted EPS steering of $10.71-$10.91. Consensus is $10.88.
